We could further identify several dementia patients with autoantibodies against GFAP and/or astrocytes, which seems an interesting new marker not only for a subacute autoimmune meningoencephalomyelitis (37–40), but also for patients with slowly progressing cognitive decline and dementia (41–44). Here, GFAP is linked to dementia.